Loading...
BVMF
BIOM3
Market cap238mUSD
Dec 05, Last price  
9.50BRL
1D
7.95%
1Q
36.69%
Jan 2017
53.71%
IPO
719.64%
Name

Biomm SA

Chart & Performance

D1W1MN
BVMF:BIOM3 chart
P/E
—
P/S
9.09
EPS
—
Div Yield, %
—
Shrs. gr., 5y
19.51%
Rev. gr., 5y
74.06%
Revenues
143m
+20.91%
6,645,0001,995,0003,017,000608,000877,000000000103,0001,566,0008,944,00058,668,000107,090,000104,954,000118,194,000142,905,000
Net income
-77m
L-4.81%
6,000-5,318,000-7,412,000-7,016,000-4,273,000-4,675,000-14,140,000-10,059,000-12,713,0008,282,000-45,608,000-38,128,000-42,562,000-55,812,000-70,767,000-80,261,000-92,559,000-81,141,000-77,238,000
CFO
-92m
L+22.81%
-5,715,000-5,310,000-4,640,000-1,784,000-7,103,000-10,508,000-19,784,000-13,899,000-38,281,000-54,405,000-44,115,000-80,852,000-96,874,000-93,784,000-62,999,000-74,785,000-91,845,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biomm S.A. operates as a biotechnology company in Brazil. It offers AFREZZA, a human insulin inhalation powder; CONFORT CARE, a moisturizing foot cream; GLARGILIN, a glargine insulin; and HERZUMA, a trastuzumab. Biomm S.A. was founded in 2001 and is based in São Paulo, Brazil.
URL
https://biomm.com/
IPO date
Sep 05, 2002
Employees
Domiciled in
BR
Incorporated in
BR

Valuation

Title
BRL in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT